• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

乙型肝炎病毒感染对 COVID-19 患者的影响：一项荟萃分析。

Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, Jilin Province, China.

Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, 130033, Jilin Province, China.

出版信息

Dig Dis Sci. 2023 Apr;68(4):1615-1631. doi: 10.1007/s10620-022-07687-2. Epub 2022 Sep 9.

DOI:10.1007/s10620-022-07687-2
PMID:36085229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9462612/
Abstract

BACKGROUND

The COVID-19 pandemic has brought new problems to patients infected with hepatitis B virus (HBV).

AIM

We aim to know the effects of HBV infection on patients with COVID-19.

METHODS

We searched PubMed, Embase, and Web of Science for data and utilized Stata 14.0 software for this meta-analysis with a random-effects model. This paper was conducted in alignment with the preferred reporting items for systematic review and meta-analysis (PRISMA) guideline.

RESULTS

In total, 37,696 patients were divided into two groups: 2591 COVID-19 patients infected with HBV in the experimental group and 35,105 COVID-19 patients not infected with HBV in the control group. Our study showed that the in-hospital mortality of the experimental group was significant higher than that of the control group (OR = 2.04, 95% CI 1.49-2.79). We also found that COVID-19 patients infected with HBV were more likely to develop severe disease (OR = 1.90, 95% CI 1.32-2.73) than COVID-19 patients not infected with HBV. Upon measuring alanine aminotransferase (SMD = 0.62, 95% CI 0.25-0.98), aspartate aminotransferase (SMD = 0.60, 95% CI 0.30-0.91), total bilirubin (SMD = 0.45, 95% CI 0.23-0.67), direct bilirubin (SMD = 0.36, 95% CI 0.24-0.47), lactate dehydrogenase (SMD = 0.32, 95% CI 0.18-0.47), we found that HBV infection led to significantly higher laboratory results in COVID-19 patients.

CONCLUSION

COVID-19 patients infected with HBV should receive more attention, and special attention should be given to various liver function indices during treatment.

摘要

背景

COVID-19 大流行给乙型肝炎病毒（HBV）感染者带来了新的问题。

目的

了解 HBV 感染对 COVID-19 患者的影响。

方法

我们检索了 PubMed、Embase 和 Web of Science 中的数据，并使用 Stata 14.0 软件进行了这项荟萃分析，采用随机效应模型。本研究遵循系统评价和荟萃分析的首选报告项目（PRISMA）指南进行。

结果

共纳入 37696 例患者，分为两组：实验组 2591 例 COVID-19 合并 HBV 感染者，对照组 35105 例 COVID-19 未合并 HBV 感染者。我们的研究表明，实验组的住院死亡率显著高于对照组（OR=2.04，95%CI 1.49-2.79）。我们还发现，COVID-19 合并 HBV 感染者比 COVID-19 未合并 HBV 感染者更容易发展为重症（OR=1.90，95%CI 1.32-2.73）。测量丙氨酸氨基转移酶（SMD=0.62，95%CI 0.25-0.98）、天冬氨酸氨基转移酶（SMD=0.60，95%CI 0.30-0.91）、总胆红素（SMD=0.45，95%CI 0.23-0.67）、直接胆红素（SMD=0.36，95%CI 0.24-0.47）、乳酸脱氢酶（SMD=0.32，95%CI 0.18-0.47）后，我们发现 HBV 感染导致 COVID-19 患者的实验室结果显著升高。

结论

COVID-19 合并 HBV 感染者应受到更多关注，治疗过程中应特别注意各种肝功能指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/cb98e1db2d5d/10620_2022_7687_Fig15_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/6565bf30cb95/10620_2022_7687_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/1b27b910e1bb/10620_2022_7687_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/737096058be9/10620_2022_7687_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/2a55154ded1f/10620_2022_7687_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/547152083154/10620_2022_7687_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/12ba95307a4f/10620_2022_7687_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/8594a0c5f411/10620_2022_7687_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/c310c81bdd58/10620_2022_7687_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/ee8f608d8d8a/10620_2022_7687_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/ac7008cea937/10620_2022_7687_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/59f5c28bc420/10620_2022_7687_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/448dcbac4c0c/10620_2022_7687_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/b355acfb7ce6/10620_2022_7687_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/e4e98a046262/10620_2022_7687_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/cb98e1db2d5d/10620_2022_7687_Fig15_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/6565bf30cb95/10620_2022_7687_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/1b27b910e1bb/10620_2022_7687_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/737096058be9/10620_2022_7687_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/2a55154ded1f/10620_2022_7687_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/547152083154/10620_2022_7687_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/12ba95307a4f/10620_2022_7687_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/8594a0c5f411/10620_2022_7687_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/c310c81bdd58/10620_2022_7687_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/ee8f608d8d8a/10620_2022_7687_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/ac7008cea937/10620_2022_7687_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/59f5c28bc420/10620_2022_7687_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/448dcbac4c0c/10620_2022_7687_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/b355acfb7ce6/10620_2022_7687_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/e4e98a046262/10620_2022_7687_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07bc/9462612/cb98e1db2d5d/10620_2022_7687_Fig15_HTML.jpg

相似文献

1
Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis.乙型肝炎病毒感染对 COVID-19 患者的影响：一项荟萃分析。
Dig Dis Sci. 2023 Apr;68(4):1615-1631. doi: 10.1007/s10620-022-07687-2. Epub 2022 Sep 9.
2
Prevalence of and risk factors for Plasmodium spp. co-infection with hepatitis B virus: a systematic review and meta-analysis.疟原虫属与乙型肝炎病毒合并感染的流行率及危险因素：系统评价和荟萃分析。
Malar J. 2020 Oct 15;19(1):368. doi: 10.1186/s12936-020-03428-w.
3
The impact of HBV infection on clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.HBV 感染对 COVID-19 患者临床结局的影响：系统评价和荟萃分析。
Epidemiol Infect. 2023 Jun 29;151:e135. doi: 10.1017/S0950268823000705.
4
Global epidemiology of HBV infection among hemodialysis patients: A systematic review and meta-analysis.全球血液透析患者乙型肝炎病毒感染的流行病学：系统评价和荟萃分析。
Microb Pathog. 2023 Jun;179:106080. doi: 10.1016/j.micpath.2023.106080. Epub 2023 Mar 21.
5
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.抗乙型肝炎病毒药物用于预防人类免疫缺陷病毒阳性且同时合并乙型肝炎病毒感染的孕妇母婴传播。
Cochrane Database Syst Rev. 2023 Jun 12;6(6):CD013653. doi: 10.1002/14651858.CD013653.pub2.
6
Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.接受血液系统恶性肿瘤化疗患者的肝炎病毒感染及严重肝功能不全发生率
Eur J Haematol. 2001 Jul;67(1):45-50. doi: 10.1034/j.1600-0609.2001.067001045.x.
7
The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.非洲血液透析患者乙型肝炎和丙型肝炎病毒的流行情况及相关因素：系统评价和荟萃分析。
PLoS One. 2021 Jun 22;16(6):e0251570. doi: 10.1371/journal.pone.0251570. eCollection 2021.
8
Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.恩替卡韦和拉米夫定治疗乙型肝炎失代偿期肝硬化的疗效：荟萃分析。
World J Gastroenterol. 2013 Oct 21;19(39):6665-78. doi: 10.3748/wjg.v19.i39.6665.
9
The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis.肯尼亚乙型肝炎病毒感染负担：系统评价和荟萃分析。
Front Public Health. 2023 Jan 26;11:986020. doi: 10.3389/fpubh.2023.986020. eCollection 2023.
10
Correlation between COVID-19 and hepatitis B: A systematic review.新型冠状病毒肺炎与乙型肝炎相关性的系统评价。
World J Gastroenterol. 2022 Dec 14;28(46):6599-6618. doi: 10.3748/wjg.v28.i46.6599.

引用本文的文献

1
Hepatitis B associated with severe COVID-19: a nationwide cohort study in Sweden.与重症新型冠状病毒肺炎相关的乙型肝炎：瑞典一项全国性队列研究
Virol J. 2025 Apr 30;22(1):127. doi: 10.1186/s12985-025-02743-5.
2
Evaluation of the impact of COVID-19 on hepatitis B in Henan Province and its epidemic trend based on Bayesian structured time series model.基于贝叶斯结构化时间序列模型评估河南省新冠肺炎对乙型肝炎的影响及其流行趋势
BMC Public Health. 2025 Apr 8;25(1):1312. doi: 10.1186/s12889-025-22305-2.
3
Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study.

本文引用的文献

1
Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis.新冠病毒与乙肝病毒合并感染的患者预后不良风险较高。
Infect Dis Ther. 2022 Jun;11(3):1229-1242. doi: 10.1007/s40121-022-00638-4. Epub 2022 Apr 26.
2
Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database.基于健康保险审查与评估服务数据库的全国性人群研究：乙型肝炎病毒对新型冠状病毒感染患者的临床影响。
J Korean Med Sci. 2022 Jan 24;37(4):e29. doi: 10.3346/jkms.2022.37.e29.
3
Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
美国慢性乙型肝炎与新冠病毒病的临床结局：一项多中心回顾性队列研究
Open Forum Infect Dis. 2025 Jan 10;12(2):ofaf013. doi: 10.1093/ofid/ofaf013. eCollection 2025 Feb.
4
Association between Hepatitis B virus infection and COVID-19: outcomes from clinical analysis and online survey from Beijing, China.乙型肝炎病毒感染与新型冠状病毒肺炎的关联：来自中国北京的临床分析与在线调查结果
BMC Infect Dis. 2024 Dec 18;24(1):1438. doi: 10.1186/s12879-024-10333-z.
5
Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.阿兹夫定与奈玛特韦/利托那韦对比及联合应用于新型冠状病毒肺炎患者的研究
Infect Drug Resist. 2023 Dec 22;16:7797-7808. doi: 10.2147/IDR.S433186. eCollection 2023.
6
The impact of HBV infection on clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.HBV 感染对 COVID-19 患者临床结局的影响：系统评价和荟萃分析。
Epidemiol Infect. 2023 Jun 29;151:e135. doi: 10.1017/S0950268823000705.
7
SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease.SARS-CoV-2 与肝脏：慢性肝病的临床和免疫学特征。
Gut. 2023 Sep;72(9):1783-1794. doi: 10.1136/gutjnl-2023-329623. Epub 2023 Jun 14.
8
Association of current hepatitis B virus infection with mortality in adults with sepsis.当前乙型肝炎病毒感染与脓毒症成人死亡率的关系。
Epidemiol Infect. 2023 May 19;151:e94. doi: 10.1017/S0950268823000729.
9
Outcomes of COVID-19 among patients with liver disease.COVID-19 患者的肝病结局。
World J Gastroenterol. 2023 Feb 7;29(5):815-824. doi: 10.3748/wjg.v29.i5.815.
10
COVID-19 Vaccination in Patients with Chronic Liver Disease.慢性肝病患者的 COVID-19 疫苗接种。
Viruses. 2022 Dec 13;14(12):2778. doi: 10.3390/v14122778.
慢性乙型肝炎感染与 COVID-19 结局的关联：一项韩国全国队列研究。
PLoS One. 2021 Oct 5;16(10):e0258229. doi: 10.1371/journal.pone.0258229. eCollection 2021.
4
Sources and clinical significance of aspartate aminotransferase increases in COVID-19.COVID-19 患者天门冬氨酸氨基转移酶升高的来源及临床意义。
Clin Chim Acta. 2021 Nov;522:88-95. doi: 10.1016/j.cca.2021.08.012. Epub 2021 Aug 16.
5
Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) /Hepatitis B virus (HBV) Co-infected Patients: A case series and review of the literature.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）/乙型肝炎病毒（HBV）合并感染患者：病例系列和文献复习。
Int J Clin Pract. 2021 Sep;75(9):e14412. doi: 10.1111/ijcp.14412. Epub 2021 Jun 6.
6
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19.目前和既往的 HBV 感染不会增加 COVID-19 患者的死亡率。
Hepatology. 2021 Oct;74(4):1750-1765. doi: 10.1002/hep.31890. Epub 2021 Jun 21.
7
Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study.COVID-19 患者合并乙型肝炎病毒感染的临床特征：一项回顾性研究。
Liver Int. 2021 Apr;41(4):720-730. doi: 10.1111/liv.14774. Epub 2021 Jan 10.
8
Association of liver abnormalities with in-hospital mortality in patients with COVID-19.COVID-19 患者肝脏异常与住院死亡率的相关性。
J Hepatol. 2021 Jun;74(6):1295-1302. doi: 10.1016/j.jhep.2020.12.012. Epub 2020 Dec 19.
9
Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis.直接胆红素比总胆红素更能预测肝硬化患者的预后。
Gut Liver. 2021 Jul 15;15(4):599-605. doi: 10.5009/gnl20171.
10
Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection.SARS-CoV-2 合并感染对慢性乙型肝炎感染的动力学无明显影响。
Virology. 2021 Jan 15;553:131-134. doi: 10.1016/j.virol.2020.11.012. Epub 2020 Nov 28.